Loading...
XNYS
MRK
Market cap363bUSD
Sep 17, Last price  
147.15USD
1D
1.55%
1Q
29.23%
Jan 2017
161.96%
Name

Merck & Co Inc

Chart & performance

D1W1MN
XNYS:MRK chart
P/E
19.91
P/S
5.60
EPS
7.39
Div yield, %
2.23%
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
9.35%
Revenues
64.93b
+1.18%
22,636,000,00024,197,700,00023,850,000,00027,428,000,00045,987,000,00048,047,000,00047,267,000,00044,033,000,00042,237,000,00039,498,000,00039,807,000,00040,122,000,00042,294,000,00039,121,000,00041,518,000,00048,704,000,00059,283,000,00060,115,000,00064,168,000,00064,926,000,000
Net income
18.25b
+6.64%
4,433,800,0003,275,400,0007,808,000,00012,899,000,000861,000,0006,272,000,0006,168,000,0004,404,000,00011,920,000,0004,442,000,0003,920,000,0002,394,000,0006,220,000,0009,843,000,0007,067,000,00013,049,000,00014,519,000,000365,000,00017,117,000,00018,254,000,000
CFO
16.47b
-23.27%
6,765,200,0006,999,200,0006,571,700,0003,392,000,00010,822,000,00012,383,000,00010,022,000,00011,654,000,0007,860,000,00012,421,000,00010,376,000,0006,447,000,00010,922,000,00013,440,000,00010,253,000,00014,109,000,00019,095,000,00013,006,000,00021,468,000,00016,472,000,000
Dividend
Sep 15, 20260.85 USD/sh
Earnings
Oct 29, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Related entities

Subsidiaries (22)
Merck Sharp & Dohme LLC
ALLFLEX INDIA PRIVATE LIMITED
INTERVET INDIA PRIVATE LIMITED
MERCK HOLDINGS LLC
Merck International Holdings LLC
MERCK SHARP & DOHME B.V.
MERCK SHARP & DOHME FINANCE EUROPE LIMITED
MERCK SHARP & DOHME MANUFACTURING UNLIMITED COMPANY
MERCK SHARP & DOHME RESEARCH GMBH
MSD ANIMAL HEALTH PENSION SCHEME
MSD FI B.V.
MSD FINANCE 2 LLC
MSD FINANCE B.V.
MSD Human Health Holding B.V.
MSD HYDERABAD GLOBAL CAPABILITIES CENTER INDIA PRIVATE LIMITED
MSD INTERNATIONAL BUSINESS GMBH
MSD INTERNATIONAL FINANCE B.V.
MSD INTERNATIONAL GMBH
MSD Netherlands Capital B.V.
MSD Pharmaceuticals Investments 3

Key people

Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division · since 2016
Richard R. DeLuca
Executive Vice President, President - Merck Animal Health · since 2011
Michael T. Nally
Executive Vice President, Chief Marketing Officer · since 2019
Michael W. Fleming
Senior Vice President, Chief Ethics and Compliance Officer · since 2019
Executive Vice President, General Counsel, Corporate Secretary · since 2020
Senior Vice President Finance - Global Controller · since 2014
Lead Independent Director · since 2016
Mary Ellen Coe
Director · since 2019
Thomas R. Cech
Independent Director · since 2009
Independent Director · since 2015
Independent Director · since 2007
Independent Director · since 2017
Paul B. Rothman
Independent Director · since 2015
Independent Director · since 1995
Independent Director · since 2020
IPO date
Jan 01, 1941
Employees
67,000
Domiciled in
US
Incorporated in
US
Legal address
c/o C T Corporation System
820 Bear Tavern Road
West Trenton
Trenton, NJ 08628-1021
US
Headquarters
126 East Lincoln Avenue
PO Box 2000
Rahway, NJ 07065-1310
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT